Indication: HER2+ Unresectable or Metastatic
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
Sub-indication: Breast Cancer
Study Type: Drug Study
Principal Investigator: Laila Agrawal, M.D.Norton Cancer Institute
Sponsor: Sponsor: AstraZeneca